Endovascular Engineering
Menlo Park, California, United States · Biotechnology, Health Care, Medical Device · 37 employees
Endovascular Engineering, Inc. ("E2") is at the forefront of transforming venous thromboembolism (VTE) treatment with the Hēlo™ Thrombectomy System, a novel technology designed for the treatment of pulmonary embolism. As a venture-backed medical technology innovator with multiple strategic investors, E2 is dedicated to developing and deploying groundbreaking solutions that advance the standard of
Funding history
- Series series c — $80.0M — Apr 2026
- Series series b — $42.0M — Feb 2025
Recent signals
- Apr 07, 2026: Raised $80.0M in Series series c
- Sep 02, 2025: E2 Appoints Justin Farry as Chief Financial Officer
- Feb 18, 2025: Raised $42.0M in Series series b
- Aug 20, 2024: Endovascular Engineering, Inc. Appoints Dan Rose as Chief Executive Officer (CEO) and Mike Rosenthal as Chief Operating Officer
See plans & pricing → Track Endovascular Engineering’s funding, hiring, and signals — with verified contacts — on Fundz.